Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. uri icon

Overview

publication date

  • October 13, 2019

Research

keywords

  • Adenocarcinoma of Lung
  • Anaplastic Lymphoma Kinase
  • Crizotinib
  • Gene Rearrangement
  • Lung Neoplasms
  • Protein Kinase Inhibitors

Identity

PubMed Central ID

  • PMC5050111

Scopus Document Identifier

  • 85074405432

Digital Object Identifier (DOI)

  • 10.1016/j.cllc.2019.10.002

PubMed ID

  • 31690489

Additional Document Info

volume

  • 21

issue

  • 1